Michael T Schweizer1,2, Gavin Ha3, Roman Gulati3, Landon C Brown4, Rana R McKay5, Tanya Dorff6, Anna C H Hoge3, Jonathan Reichel3, Pankaj Vats7, Deepak Kilari8, Vaibhav Patel9, William K Oh9, Arul Chinnaiyan7, Colin C Pritchard10, Andrew J Armstrong4, R Bruce Montgomery1,11, Ajjai Alva7. 1. Department of Medicine, University of Washington, Seattle, WA. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Duke Cancer Institute Center for Prostate and Urologic Cancers, Departments of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke University, Durham, NC. 5. University of California San Diego, San Diego, CA. 6. City of Hope, Duarte, CA. 7. University of Michigan, Ann Arbor, MI. 8. Medical College of Wisconsin, Wauwatosa, WI. 9. Icahn School of Medicine at Mount Sinai, New York, NY. 10. Department of Laboratory Medicine, University of Washington, Seattle, WA. 11. Puget Sound VA, Seattle, WA.
Abstract
PURPOSE: Translational studies have shown that CDK12 mutations may delineate an immunoresponsive subgroup of prostate cancer, characterized by high neo-antigen burden. Given that these mutations may define a clinically distinct subgroup, we sought to describe outcomes to standard drugs and checkpoint inhibitors (CPI). PATIENTS AND METHODS: Clinical data from consecutive patients with CDK12 mutations were retrospectively collected from 7 centers. Several clinical-grade sequencing assays were used to assess CDK12 status. Descriptive statistics included PSA50 response rate (≥ 50% decline in prostate-specific antigen from baseline) and clinical/radiographic progression-free survival (PFS). RESULTS: Of 52 patients with CDK12-mutated prostate cancer, 27 (52%) had detected biallelic CDK12 alterations. At diagnosis, 44 (88%) had Gleason grade group 4-5, 52% had T3-T4, and 14 (27%) had M1 disease. Median follow-up was 8.2 years (95% CI, 5.6 to 11.1 years), and 49 (94%) developed metastatic disease. Median overall survival from metastasis was 3.9 years (95% CI, 3.2 to 8.1 years). Unconfirmed PSA50 response rates to abiraterone and enzalutamide in the first-line castration-resistant prostate cancer setting were 11 of 17 (65%) and 9 of 12 (75%), respectively. Median PFS on first-line abiraterone and enzalutamide was short, at 8.2 months (95% CI, 6.6 to 12.6 months) and 10.6 months (95% CI, 10.2 months to not reached), respectively. Nineteen patients received CPI therapy. PSA50 responses to CPI were noted in 11%, and PFS was short; however, the estimated 9-month PFS was 23%. PFS was higher in chemotherapy-näıve versus chemotherapypretreated patients (median PFS: not reached v 2.1 months, P = .004). CONCLUSION: CDK12 mutations define an aggressive prostate cancer subgroup, with a high rate of metastases and short overall survival. CPI may be effective in a minority of these patients, and exploratory analysis supports using anti-programmed cell death protein 1 drugs early. Prospective studies testing CPI in this subset of patients with prostate cancer are warranted.
PURPOSE: Translational studies have shown that CDK12 mutations may delineate an immunoresponsive subgroup of prostate cancer, characterized by high neo-antigen burden. Given that these mutations may define a clinically distinct subgroup, we sought to describe outcomes to standard drugs and checkpoint inhibitors (CPI). PATIENTS AND METHODS: Clinical data from consecutive patients with CDK12 mutations were retrospectively collected from 7 centers. Several clinical-grade sequencing assays were used to assess CDK12 status. Descriptive statistics included PSA50 response rate (≥ 50% decline in prostate-specific antigen from baseline) and clinical/radiographic progression-free survival (PFS). RESULTS: Of 52 patients with CDK12-mutated prostate cancer, 27 (52%) had detected biallelic CDK12 alterations. At diagnosis, 44 (88%) had Gleason grade group 4-5, 52% had T3-T4, and 14 (27%) had M1 disease. Median follow-up was 8.2 years (95% CI, 5.6 to 11.1 years), and 49 (94%) developed metastatic disease. Median overall survival from metastasis was 3.9 years (95% CI, 3.2 to 8.1 years). Unconfirmed PSA50 response rates to abiraterone and enzalutamide in the first-line castration-resistant prostate cancer setting were 11 of 17 (65%) and 9 of 12 (75%), respectively. Median PFS on first-line abiraterone and enzalutamide was short, at 8.2 months (95% CI, 6.6 to 12.6 months) and 10.6 months (95% CI, 10.2 months to not reached), respectively. Nineteen patients received CPI therapy. PSA50 responses to CPI were noted in 11%, and PFS was short; however, the estimated 9-month PFS was 23%. PFS was higher in chemotherapy-näıve versus chemotherapypretreated patients (median PFS: not reached v 2.1 months, P = .004). CONCLUSION:CDK12 mutations define an aggressive prostate cancer subgroup, with a high rate of metastases and short overall survival. CPI may be effective in a minority of these patients, and exploratory analysis supports using anti-programmed cell death protein 1 drugs early. Prospective studies testing CPI in this subset of patients with prostate cancer are warranted.
Authors: Ethan S Sokol; Dean Pavlick; Garrett M Frampton; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Tamara L Lotan; Drew M Pardoll; Jon H Chung; Emmanuel S Antonarakis Journal: Oncologist Date: 2019-07-10
Authors: Xiao X Wei; Jaselle Perry; Emily Chang; Li Zhang; Robert A Hiatt; Charles J Ryan; Eric J Small; Lawrence Fong Journal: Clin Genitourin Cancer Date: 2017-12-27 Impact factor: 2.872
Authors: Tomasz M Beer; Eugene D Kwon; Charles G Drake; Karim Fizazi; Christopher Logothetis; Gwenaelle Gravis; Vinod Ganju; Jonathan Polikoff; Fred Saad; Piotr Humanski; Josep M Piulats; Pablo Gonzalez Mella; Siobhan S Ng; Dirk Jaeger; Francis X Parnis; Fabio A Franke; Javier Puente; Roman Carvajal; Lisa Sengeløv; M Brent McHenry; Arvind Varma; Alfonsus J van den Eertwegh; Winald Gerritsen Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Arun A Azad; Stanislav V Volik; Alexander W Wyatt; Anne Haegert; Stephane Le Bihan; Robert H Bell; Shawn A Anderson; Brian McConeghy; Robert Shukin; Jenny Bazov; Jack Youngren; Pamela Paris; George Thomas; Eric J Small; Yuzhuo Wang; Martin E Gleave; Colin C Collins; Kim N Chi Journal: Clin Cancer Res Date: 2015-02-23 Impact factor: 12.531
Authors: Paul F Schellhammer; Gerald Chodak; James B Whitmore; Robert Sims; Mark W Frohlich; Philip W Kantoff Journal: Urology Date: 2013-04-09 Impact factor: 2.649
Authors: Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky Journal: Nat Biotechnol Date: 2013-10-20 Impact factor: 54.908
Authors: Colin C Pritchard; Stephen J Salipante; Karen Koehler; Christina Smith; Sheena Scroggins; Brent Wood; David Wu; Ming K Lee; Suzanne Dintzis; Andrew Adey; Yajuan Liu; Keith D Eaton; Renato Martins; Kari Stricker; Kim A Margolin; Noah Hoffman; Jane E Churpek; Jonathan F Tait; Mary-Claire King; Tom Walsh Journal: J Mol Diagn Date: 2013-11-02 Impact factor: 5.568
Authors: N W Clarke; A Ali; F C Ingleby; A Hoyle; C L Amos; G Attard; C D Brawley; J Calvert; S Chowdhury; A Cook; W Cross; D P Dearnaley; H Douis; D Gilbert; S Gillessen; R J Jones; R E Langley; A MacNair; Z Malik; M D Mason; D Matheson; R Millman; C C Parker; A W S Ritchie; H Rush; J M Russell; J Brown; S Beesley; A Birtle; L Capaldi; J Gale; S Gibbs; A Lydon; A Nikapota; A Omlin; J M O'Sullivan; O Parikh; A Protheroe; S Rudman; N N Srihari; M Simms; J S Tanguay; S Tolan; J Wagstaff; J Wallace; J Wylie; A Zarkar; M R Sydes; M K B Parmar; N D James Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz Journal: Nature Date: 2013-06-16 Impact factor: 49.962
Authors: Harsimar B Kaur; Thiago Vidotto; Adrianna A Mendes; Daniela C Salles; William B Isaacs; Emmanuel S Antonarakis; Tamara L Lotan Journal: Cancer Immunol Immunother Date: 2021-09-17 Impact factor: 6.630
Authors: Eshwari Dathathri; Khrystany T Isebia; Fikri Abali; Martijn P Lolkema; John W M Martens; Leon W M M Terstappen; Ruchi Bansal Journal: Front Oncol Date: 2022-05-20 Impact factor: 5.738
Authors: Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S de Bono Journal: Clin Cancer Res Date: 2020-09-28 Impact factor: 13.801
Authors: Eric Powers; Georgia Sofia Karachaliou; Chester Kao; Michael R Harrison; Christopher J Hoimes; Daniel J George; Andrew J Armstrong; Tian Zhang Journal: J Hematol Oncol Date: 2020-10-28 Impact factor: 17.388